Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy.

Mitsui Y, Sadahira T, Maruyama Y, Wada K, Tanimoto R, Sugimoto M, Araki M, Watanabe M, Yanai H, Watanabe T, Nasu Y.

Acta Med Okayama. 2018 Dec;72(6):605-609. doi: 10.18926/AMO/56380.

2.
3.

HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.

Varinot J, Furudoï A, Drouin S, Phe V, Penna RR, Roupret M, Bitker MO, Cussenot O, Compérat E.

Virchows Arch. 2016 May;468(5):619-22. doi: 10.1007/s00428-016-1917-x. Epub 2016 Mar 1.

PMID:
26931741
4.

A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.

Iwamura H, Hatakeyama S, Tanaka Y, Tanaka T, Tokui N, Yamamoto H, Imai A, Yoneyama T, Hashimoto Y, Koie T, Yoshikawa K, Ohyama C.

BMC Res Notes. 2014 Jan 29;7:64. doi: 10.1186/1756-0500-7-64.

5.

Cancer of unknown primary finally revealed to be a metastatic prostate cancer: a case report.

Cho JY, Shim EJ, Kim IS, Nam EM, Choi MY, Lee KE, Mun YC, Seoung CM, Lee SN, Song DE, Han WS.

Cancer Res Treat. 2009 Mar;41(1):45-9. doi: 10.4143/crt.2009.41.1.45. Epub 2009 Mar 31.

6.

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR.

PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.

7.

[A case of prostate cancer diagnosed pathologically by bone metastatic site biopsy].

Nakata S, Nakano K, Takahashi H, Shimizu K, Higashi H, Ohki K.

Nihon Hinyokika Gakkai Zasshi. 2005 May;96(4):507-10. Japanese.

8.

NKX3.1 as a marker of prostatic origin in metastatic tumors.

Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM.

Am J Surg Pathol. 2010 Aug;34(8):1097-105. doi: 10.1097/PAS.0b013e3181e6cbf3.

9.

[Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report].

Yamada Y, Fujiwara H, Somiya S, Fujikawa S, Kamiyama Y, Tamaki M, Kanaoka T.

Hinyokika Kiyo. 2018 Apr;64(4):187-192. doi: 10.14989/ActaUrolJap_64_4_187. Japanese.

PMID:
29772622
10.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
11.

Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Epstein JI, Egevad L, Humphrey PA, Montironi R; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group.

Am J Surg Pathol. 2014 Aug;38(8):e6-e19. doi: 10.1097/PAS.0000000000000238.

PMID:
25029122
12.

The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.

Pan X, Zhang X, Gong J, Tan J, Yin X, Tang Q, Shu K, Shen P, Zeng H, Chen N.

Prostate. 2016 Jun;76(9):823-33. doi: 10.1002/pros.23173. Epub 2016 Mar 8.

PMID:
27159572
13.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
14.

Bilateral Testicular Metastases from Occult Primary Prostate Cancer in a Young Adult: A Rare Case Report.

Kamble VR, Agrawal PM.

J Clin Diagn Res. 2017 May;11(5):TD03-TD05. doi: 10.7860/JCDR/2017/25292.9783. Epub 2017 May 1.

15.

Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.

Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, Stattin P, Widmark A, Bergh A, Wikström P.

Eur Urol. 2017 May;71(5):776-787. doi: 10.1016/j.eururo.2016.07.033. Epub 2016 Aug 3.

16.

Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population.

Steiner H, Moser P, Hager M, Berger AP, Klocker H, Spranger R, Rogatsch H, Bartsch G, Horninger W.

Prostate. 2004 Feb 15;58(3):277-82.

PMID:
14743467
17.

Pneumothorax as a Presenting Clinical Manifestation of Metastatic Prostate Cancer.

Chiang KH, Hung SH, Chang ST.

World J Oncol. 2013 Apr;4(2):118-121. doi: 10.4021/wjon630w. Epub 2013 May 6.

18.

Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.

Thysell E, Surowiec I, Hörnberg E, Crnalic S, Widmark A, Johansson AI, Stattin P, Bergh A, Moritz T, Antti H, Wikström P.

PLoS One. 2010 Dec 3;5(12):e14175. doi: 10.1371/journal.pone.0014175.

19.

NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.

Huang H, Guma SR, Melamed J, Zhou M, Lee P, Deng FM.

Am J Clin Exp Urol. 2018 Oct 20;6(5):182-188. eCollection 2018.

20.

Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis.

Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET.

Prostate. 2008 Sep 15;68(13):1396-404. doi: 10.1002/pros.20805.

Supplemental Content

Support Center